Treatment of inflammatory diseases using placental stem cells

Patent metadata

Field	Value
Publication number	US-2017007648-A1
Application number	US-201615271429-A
Country	US
Kind code	A1
Filing date	Sep 21, 2016
Priority date	Feb 12, 2007
Publication date	Jan 12, 2017
Grant date	—

Abstract

Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.

First claim

What is claimed:

1 . A method of treating an individual having or at risk of developing a disease, disorder or condition associated with or caused by an inappropriate or unwanted immune response, comprising administering to the individual a therapeutically effective amount of placental stem cells, or culture medium conditioned by placental stem cells, wherein the therapeutically effective amount is an amount sufficient to cause a detectable improvement in one or more symptoms of said disease, disorder or condition.

2 . The method of claim 1 , wherein said placental stem cell is a CD10 + , CD34 − , CD105 + , CD200 + placental stem cell.

3 . The method of claim 1 , wherein said placental stem cells express CD200 and HLA-G, or express CD73, CD105, and CD200, or express CD200 and OCT-4, or express CD73, CD105 and HLA-G, or express CD73 and CD105 and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow for the formation of an embryoid-like body, or express OCT-4 and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow for the formation of an embryoid-like body.

4 . The method of claim 2 , wherein said disease, disorder or condition is scleroderma.

5 . The method of claim 4 , wherein the scleroderma is diffuse scleroderma.

6 . The method of claim 4 , wherein the scleroderma is limited scleroderma (CREST syndrome).

7 . The method of claim 4 , wherein the scleroderma is morphea/linear scleroderma.

8 . The method of claim 4 , wherein said symptom is one or more of hardening of the skin of the face, hardening of the skin of the fingers, Reynaud's syndrome, inappropriate vasoconstriction in an extremity, calcinosis, telangiectasia, esophageal dysmotility, or presence in the blood of an anti-centromere antibody or an anti-scl70/anti-topoisomerase antibody.

9 . The method of claim 4 , comprising administering a second therapeutic agent to said individual.

10 . The method of claim 9 , wherein said second therapeutic agent is an anti-inflammatory drug, a proton pump inhibitor, an immunosuppressant compound, or a vasodilator.

11 . The method of claim 2 , wherein said disease, disorder or condition is mycosis fungoides (Alibert-Bazin syndrome).

12 . The method of claim 11 , wherein said mycosis fungoides is in the patch phase.

13 . The method of claim 11 , wherein said mycosis fungoides is in the skin tumor phase.

14 . The method of claim 11 , wherein said mycosis fungoides is in the skin redness (erythroderma) stage.

15 . The method of claim 11 , wherein said mycosis fungoides is in the lymph node stage.

16 . The method of claim 11 , wherein said symptom is one or more of development of flat, red patches that are itchy; development of flat, red patches that are raised and hard (plaques); development of raised lumps (nodules) appear; development of large red, itchy, scaly areas over the body; cracking of the skin of the palms and soles; thickening of the skin of the palms and soles; and crack; or inflammation of the lymph nodes.

17 . The method of claim 11 , comprising administering a second therapeutic agent to said individual.

18 . The method of claim 9 , wherein said second therapeutic agent is an anti-inflammatory drug, an immunosuppressant compound, exposure to sunlight, exposure to ultraviolet light, a topical steroid, local superficial radiotherapy, total skin electron beam radiation, application of organic honey to skin affected by erythorderma, an interferon, a retinoid, a rexinoid, or vorinostat.

Assignees

• Anthrogenesis Corp

Inventors

• Edinger James W
• Hariri Robert J
• Wang Jia-Lun
• Ye Qian
• Faleck Herbert

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P9/14

  Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title